Is a complete QNCX research report available?

No complete published report is available for Quince Therapeutics, Inc. (QNCX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Quince Therapeutics, Inc. (QNCX)

NASDAQ: QNCX · USD

$23.0

+1.03 (+4.7%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first QNCX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	22.5M
Net income (ttm)	-36.2M
EPS (ttm)	-$137
Shares out	978K
Volume	58,698
Beta	1.40
Price target	$83.0	+260.4%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -36.2M
EPS (ttm): -$137
Market cap: 22.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All QNCX indicators

Market & fundamental data

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001145404
Company name	Quince Therapeutics, Inc.
Country	United States
Country code	US
Cusip	22053A305
Employees	38
Employees Change	2%
Employees Change Percent	5.56
Enterprise value	$4.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-05-09
Isin	US22053A3059
Last refreshed	2026-07-31
Market cap	$22.5M
Market cap category	Nano-Cap
Price	$23.03
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	QNCX
Website	https://quincetx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-162.15%
FCF yield	-177.84%
P/B ratio	0.97x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-36.2M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Profit Per Employee	$-951,447
Profitable Quarters	$1
ROA	-45.44
Roa5y	-23.81
ROCE	-323.7
ROE	-192.9
ROIC	-120.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-93.16%
Cagr3y	-53.95%
Cagr5y	-70.99%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$26.6M
Cash	$18.2M
Current Assets	$25.6M
Current Liabilities	$8.8M
Debt	$406,000
Debt Equity	$0.03
Equity	$15.7M
Interest Coverage	-63.24
Liabilities	$11M
Long Term Assets	$1M
Long Term Liabilities	$2.2M
Net Cash	$17.8M
Net Cash By Market Cap	$79.64
Net Cash Growth	12.05%
Net Debt Equity	$-1.13
Tangible Book Value	$15.7M
Tangible Book Value Per Share	$22.73
WACC	14.92

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.92
Net Working Capital	$-1.2M
Quick ratio	2.82
Working Capital	$16.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-42.34%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-93.15%
200-day SMA	216.8
3Y total return	-90.24%
50-day SMA	19.49
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.79%
All Time High	24,396
All Time High Change	-99.91%
All Time High Date	2021-08-10
All Time Low	15.1
All Time Low Change	52.52%
All Time Low Date	2026-07-01
ATR	1.69
Beta	1.4
Beta1y	2.23
Beta2y	0.42
Ch YTD	-96.56
High	23.66
High52	910
High52 Date	2025-12-12
High52ch	-97.47%
Low	21.76
Low52	15.1
Low52 Date	2026-07-01
Low52ch	52.52%
Ma50ch	18.16%
Premarket Change Percent	-0.91
Premarket Price	$21.8
Price vs 200-day SMA	-89.38%
RSI	70.58
RSI Monthly	38.86
RSI Weekly	34.93
Sharpe ratio	0.49x
Sortino ratio	1.31
Total Return	-42.34%
Tr YTD	-96.56
Tr1m	25.08%
Tr1w	25.99%
Tr3m	-6.38%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	2
Analyst Price Target Top	$89.5
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-7.79
Operating Income	$-48.6M
Price target	$83
Price Target Change	$260
Price Target Change Top	$289

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	878,174%
Float Percent	89.8%
Net Borrowing	-5,545,000
Shares Insiders	3.03%
Shares Institutions	8.49%
Shares Out	977,962
Shares Qo Q	65.04%
Shares Yo Y	42.34%
Short Float	5.76%
Short Ratio	1.56
Short Shares	5.17

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-44.7M
Adjusted OCF	-44,456,000
Average Volume	37,147.6x
Bv Per Share	22.73
CAPEX	$-204,000
Ch1m	25.08
Ch1w	25.99
Ch1y	-93.15
Ch3m	-6.38
Ch3y	-90.24
Ch5y	-99.79
Ch6m	-57.37
Change	4.68%
Change From Open	5.59
Close	22
Days Gap	-0.86
Depreciation Amortization	146,000
Dollar Volume	1,351,814.9
Earnings Date	2026-08-12
Earnings Time	amc
EBIT	$-57.8M
EBITDA	$-57.6M
EPS	$-137
F Score	0
FCF	$-39.7M
FCF EV Yield	-873.36x
FCF Per Share	$-40.55
Financing CF	27,265,000
Fiscal Year End	December
Founded	2,012
Income Tax	$-2.2M
Investing CF	24,329,000
Ipr	34.12
Iprfo	-99.43
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-11
Last Report Date	2026-03-31
Last Split Date	2026-06-30
Last Split Type	Reverse
Ma150	121.6
Ma150ch	-81.06%
Ma20	18.56
Ma20ch	24.09%
Net CF	10,392,000
Next Earnings Date	2026-08-10
Open	21.81
Optionable	Yes
Position In Range	66.84
Post Close	23.03
Postmarket Change Percent	-2
Postmarket Price	$22.57
Ppne	965,000
Pre Close	22
Price Date	2026-07-30
Ptbv Ratio	1.42
Relative Volume	1.58x
Share Based Comp	5,005,000
Tr6m	-57.37%
Us State	California
Volume	58,698

Quince Therapeutics, Inc. (QNCX)

Coverage state: Market snapshot only — no published research

Generate the first QNCX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · QNCX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All QNCX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on QNCX

Frequently asked questions